Trials / Completed
CompletedNCT00117130
Study to Evaluate Effectiveness of Aranesp®
Aranesp® Monthly Preference Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aranesp® |
Timeline
- First posted
- 2005-07-04
- Last updated
- 2011-01-21
Source: ClinicalTrials.gov record NCT00117130. Inclusion in this directory is not an endorsement.